BNTC Stock Overview
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines.
Benitec Biopharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.00|
|52 Week High||US$5.07|
|52 Week Low||US$0.90|
|1 Month Change||-46.97%|
|3 Month Change||-57.35%|
|1 Year Change||-77.83%|
|3 Year Change||-95.82%|
|5 Year Change||-97.07%|
|Change since IPO||-99.71%|
Recent News & Updates
We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|BNTC||US Biotechs||US Market|
Return vs Industry: BNTC underperformed the US Biotechs industry which returned -22.1% over the past year.
Return vs Market: BNTC underperformed the US Market which returned -15.1% over the past year.
|BNTC Average Weekly Movement||11.8%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: BNTC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: BNTC's weekly volatility (12%) has been stable over the past year.
About the Company
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection.
Benitec Biopharma Fundamentals Summary
|BNTC fundamental statistics|
Is BNTC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BNTC income statement (TTM)|
|Cost of Revenue||US$1.00k|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.10|
|Net Profit Margin||-22,858.67%|
How did BNTC perform over the long term?See historical performance and comparison
Is Benitec Biopharma undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BNTC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BNTC's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: BNTC is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Biotechs industry average.
PE vs Market: BNTC is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BNTC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BNTC is good value based on its Price-To-Book Ratio (1.1x) compared to the US Biotechs industry average (1.4x).
How is Benitec Biopharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BNTC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BNTC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BNTC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BNTC's revenue is expected to decline over the next 3 years (-73.1% per year).
High Growth Revenue: BNTC's revenue is forecast to decline over the next 3 years (-73.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BNTC's Return on Equity is forecast to be high in 3 years time
How has Benitec Biopharma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BNTC is currently unprofitable.
Growing Profit Margin: BNTC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BNTC is unprofitable, and losses have increased over the past 5 years at a rate of 29.1% per year.
Accelerating Growth: Unable to compare BNTC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BNTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: BNTC has a negative Return on Equity (-227.98%), as it is currently unprofitable.
How is Benitec Biopharma's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BNTC's short term assets ($8.8M) exceed its short term liabilities ($1.9M).
Long Term Liabilities: BNTC's short term assets ($8.8M) exceed its long term liabilities ($635.0K).
Debt to Equity History and Analysis
Debt Level: BNTC is debt free.
Reducing Debt: BNTC has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BNTC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BNTC has less than a year of cash runway if free cash flow continues to grow at historical rates of 0.5% each year.
What is Benitec Biopharma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BNTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BNTC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BNTC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BNTC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BNTC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jerel Banks (46 yo)
Dr. Jerel A. Banks, Ph D., M.D. has been the Chief Executive Officer of Benitec Biopharma Inc. since June 26, 2018. Dr. Banks serves as the Executive Chairman of the Board at Benitec Biopharma Inc. since O...
CEO Compensation Analysis
Compensation vs Market: Jerel's total compensation ($USD1.40M) is above average for companies of similar size in the US market ($USD771.12K).
Compensation vs Earnings: Jerel's compensation has increased whilst the company is unprofitable.
Experienced Management: BNTC's management team is seasoned and experienced (5.8 years average tenure).
Experienced Board: BNTC's board of directors are considered experienced (6.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4%.
Benitec Biopharma Inc.'s employee growth, exchange listings and data sources
- Name: Benitec Biopharma Inc.
- Ticker: BNTC
- Exchange: NasdaqCM
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$8.190m
- Shares outstanding: 8.17m
- Website: https://benitec.com
Number of Employees
- Benitec Biopharma Inc.
- 3940 Trust Way
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/26 00:00|
|End of Day Share Price||2022/05/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.